GAC, It is my understanding that the DSMB is only looking at the data from the perspective of primarily safety and also efficacy from the standpoint of whether patients are being unnecessarily subjected to a new drug that is wasting their time so to speak. My understanding is the SSRA will be looking at the same data but from the perspective of obtaining statistical significance and whether patients need to be added to obtain a statistically significant result. Again my understanding, but given that the company knows the total number of events occurred but is blinded to the actual events in test versus placebo it is very bold of DM to say that the study won’t need additional patients until the SSRA is out.  Yes the study is theoretically properly powered and the event rate is apparently occurring at what they predicted. To me that is promising but by no means a guarantee of no additional patient requirements or ultimate success. As with many RVX management statements perhaps a 10 to 20 pound grain of salt is required here.